Mirzaten (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is prescribed to treat major depressive disorder in adult patients, helping to improve mood, sleep, and appetite. The drug works by enhancing noradrenergic and serotonergic neurotransmission, which can alleviate depressive symptoms.

GNH USA supplies Mirzaten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products that meet European regulatory standards and providing reliable logistics for global distribution.

Mirtazapine is indicated for the treatment of major depressive disorder, a mood‑disorder condition.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients.

Common side effects are generally mild to moderate and may diminish with continued therapy.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior, especially early in treatment - Serotonin syndrome when combined with other serotonergic agents - Hepatic dysfunction - Unusual bleeding or clotting abnormalities

Before initiating therapy, clinicians should assess patient history and monitor for specific concerns.

- Monitor weight: patients may experience significant weight gain. - Assess liver function: use caution in hepatic impairment. - Evaluate for suicidal ideation: especially during the first weeks of treatment. - Review concomitant medications: avoid use with MAO inhibitors. - Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal symptoms. - Store at ambient temperature (below 25°C): keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes; interactions are grouped by clinical relevance.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CNS depressants or alcohol: additive sedation. - Antihistamines: may enhance sedative effect. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - CYP3A4 inducers (e.g., carbamazepine, rifampicin): may reduce efficacy. - Warfarin: potential alteration of INR, monitor coagulation parameters.